Skip to main content
. 2023 Jan 24;8(2):e154314. doi: 10.1172/jci.insight.154314

Figure 7. Independent of metabolic parameters, DPP4 concentration and activity decrease with HCV clearance and viral treatment.

Figure 7

Changes in plasma (A) AST, (B) ALT, and (C) C-reactive protein (CRP) levels; (D) DPP4 concentration; (E) DPP4 activity; and concentration of cytokines and chemokines that are known substrates of DPP4, including (F) IP-10, (G) MIP-1α, (H) Eotaxin, and (I) sICAM-1, in patients (n = 5–6) with HOMA-IR > 2 treated for HCV. Time points: BL, baseline; week 12, end of treatment; follow-up, 24 to 48 weeks after treatment. Groups: RBV+, HCV treatment containing ribavirin in participants without cirrhosis; RBV−, ribavirin-free HCV treatment in participants without cirrhosis; RBV+F4+, HCV treatment containing ribavirin in participants with cirrhosis. To remove the variance in trait values attributed to sex and age differences, a linear regression model compared the retrieved residuals (adjusted trait values) using unpaired Student’s t test. Data are presented as the mean ± SD, and *P < 0.05.